Medtronic is on track to bring its unique extravascular implantable cardioverter defibrillator (EV ICD) to market in the next year after results from the pivotal trial of the device showed it can safely and reliably terminate ventricular arrhythmias.
Like traditional ICDs, Medtronic’s EV ICD can terminate ventricular arrhythmias with shocks of up to 40 joules, but it has a single substernal lead instead of a transvenous lead. EV...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?